WEST LAFAYETTE, Ind., Aug. 2, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced financial results for the second quarter ending June 30, 2012, and provided a business update.
